Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: aknahow who wrote (7877)	11/29/1998 8:19:00 PM
From: Bluegreen	Respond to of 17367

George, would a molecule that helped antibiotics more rapidly kill bacteria be useful? If that was the case would starting up the sepsis cascade be hampered? Would the rapidity of response be the major force in preventing sepsis? Wouldn't it make sense that fewer LPS particles by inhibiting replication of bacterial beasties(by bacterial cell death) be the MAIN key in shutting down sepsis before it really begins? Would it help to ask why EVERY bacteremia doesn't turn into full blown sepsis? Now why is that? Do most people think that there isn't degrees or stages of sepsis? Does quantity and how rapidly the response have anything to do with it? Would it help to ask how much load of bacteria had to be given in experiments in regards to BPI? What if you had a molecule that literally poked holes in gram neg bacteria by electrostatic forces that allowed modern day worthless antibiotics to work again? Anticipate the RAPID possibilities. Imagine finding a company that had a molecule like that with a DSMB coming up in a few weeks. George, what would you think?